Cargando…

Immunotherapy of Neuromyelitis Optica

Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bienia, Benjamin, Balabanov, Roumen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886592/
https://www.ncbi.nlm.nih.gov/pubmed/24455211
http://dx.doi.org/10.1155/2013/741490
_version_ 1782478902254370816
author Bienia, Benjamin
Balabanov, Roumen
author_facet Bienia, Benjamin
Balabanov, Roumen
author_sort Bienia, Benjamin
collection PubMed
description Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as active elimination of proinflammatory molecules from the peripheral blood circulation, can attenuate disease progression. In this review, we discuss the immunotherapeutic options and the treatment strategies in NMO. We also analyze the pathogenic mechanisms of the disease in order to provide recommendations regarding treatments.
format Online
Article
Text
id pubmed-3886592
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38865922014-01-22 Immunotherapy of Neuromyelitis Optica Bienia, Benjamin Balabanov, Roumen Autoimmune Dis Review Article Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as active elimination of proinflammatory molecules from the peripheral blood circulation, can attenuate disease progression. In this review, we discuss the immunotherapeutic options and the treatment strategies in NMO. We also analyze the pathogenic mechanisms of the disease in order to provide recommendations regarding treatments. Hindawi Publishing Corporation 2013 2013-12-25 /pmc/articles/PMC3886592/ /pubmed/24455211 http://dx.doi.org/10.1155/2013/741490 Text en Copyright © 2013 B. Bienia and R. Balabanov. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Bienia, Benjamin
Balabanov, Roumen
Immunotherapy of Neuromyelitis Optica
title Immunotherapy of Neuromyelitis Optica
title_full Immunotherapy of Neuromyelitis Optica
title_fullStr Immunotherapy of Neuromyelitis Optica
title_full_unstemmed Immunotherapy of Neuromyelitis Optica
title_short Immunotherapy of Neuromyelitis Optica
title_sort immunotherapy of neuromyelitis optica
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886592/
https://www.ncbi.nlm.nih.gov/pubmed/24455211
http://dx.doi.org/10.1155/2013/741490
work_keys_str_mv AT bieniabenjamin immunotherapyofneuromyelitisoptica
AT balabanovroumen immunotherapyofneuromyelitisoptica